Eupraxia Pharmaceuticals (EPRX) Projected to Release Quarterly Earnings on Monday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is anticipated to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 5.5 %

Shares of Eupraxia Pharmaceuticals stock opened at $2.93 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48. The stock has a market capitalization of $104.41 million and a P/E ratio of -4.07. The business’s fifty day moving average price is $3.54 and its 200 day moving average price is $3.16.

Analysts Set New Price Targets

Separately, Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Friday, February 21st. They issued a “buy” rating and a $12.00 price target for the company.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.